Novavax, Inc. (NASDAQ:NVAX) Receives Average Recommendation of “Hold” from Analysts

Novavax, Inc. (NASDAQ:NVAX) has been given a consensus rating of “Hold” by the nine brokerages that are presently covering the stock, Marketbeat reports. Four analysts have rated the stock with a sell recommendation, one has assigned a hold recommendation and four have given a buy recommendation to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $11.25.

A number of research firms have commented on NVAX. Weiss Ratings restated a “sell (d+)” rating on shares of Novavax in a research note on Monday, December 29th. BTIG Research restated a “buy” rating and set a $19.00 price objective on shares of Novavax in a research report on Tuesday, January 20th. TD Cowen lowered their target price on shares of Novavax from $8.00 to $7.00 and set a “hold” rating on the stock in a research note on Tuesday, November 4th. JPMorgan Chase & Co. cut their price target on Novavax from $7.00 to $6.00 and set an “underweight” rating for the company in a research note on Tuesday, November 18th. Finally, B. Riley Financial reissued a “buy” rating and set a $16.00 price target (down from $18.00) on shares of Novavax in a report on Monday, November 10th.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NVAX. Allianz Asset Management GmbH grew its stake in shares of Novavax by 162.6% in the 3rd quarter. Allianz Asset Management GmbH now owns 1,409,734 shares of the biopharmaceutical company’s stock worth $12,222,000 after buying an additional 872,987 shares in the last quarter. TSP Capital Management Group LLC raised its position in shares of Novavax by 3.5% during the 2nd quarter. TSP Capital Management Group LLC now owns 1,399,065 shares of the biopharmaceutical company’s stock valued at $8,814,000 after buying an additional 46,900 shares in the last quarter. Allspring Global Investments Holdings LLC bought a new position in shares of Novavax in the 2nd quarter valued at about $185,000. Campbell & CO Investment Adviser LLC purchased a new position in Novavax in the second quarter worth about $1,193,000. Finally, Jupiter Asset Management Ltd. grew its position in Novavax by 195.9% in the second quarter. Jupiter Asset Management Ltd. now owns 880,410 shares of the biopharmaceutical company’s stock worth $5,547,000 after acquiring an additional 582,858 shares in the last quarter. 53.04% of the stock is currently owned by institutional investors.

Novavax Stock Down 0.3%

NVAX stock opened at $9.20 on Friday. The business’s 50-day moving average price is $8.01 and its 200-day moving average price is $7.97. The stock has a market cap of $1.50 billion, a P/E ratio of 5.14 and a beta of 2.58. The company has a quick ratio of 2.24, a current ratio of 2.27 and a debt-to-equity ratio of 5.93. Novavax has a twelve month low of $5.01 and a twelve month high of $10.64.

Novavax Company Profile

Novavax, Inc is a clinical-stage biotechnology company headquartered in Gaithersburg, Maryland, that specializes in the discovery, development and commercialization of next-generation vaccines to prevent serious infectious diseases. Founded in 1987, the company has built a platform based on recombinant nanoparticle technology and its proprietary Matrix-M™ adjuvant to enhance immune responses.

The company’s lead product is NVX-CoV2373, a protein-based vaccine designed to elicit a robust immune response against the SARS-CoV-2 virus.